



2024/4/12

產業類別 光學鏡片	
投資建議 買進	
收盤價 NT\$ 2380.00	目標價 NT\$ 3020.00

本次報告：法說會

交易資料

潛在報酬率 (%)	26.89
52 週還原收盤價區間 (NT\$)	1899.21-2824.21
市值 (NT\$百萬元)	317730
市值 (US\$百萬美元)	9,923
流通在外股數 (百萬股)	134.00
董監持股 (%)	18.60
外資持股 (%)	36.38
投信持股 (%)	2.99
融資使用率 (%)	3.21

財務資料

	2023
股東權益 (NT\$百萬元)	165,510
ROA (%)	9.42
ROE (%)	11.17
淨負債比率 (%)	15.18

公司簡介

大立光成立於 1987 年，主要生產光學鏡頭及鏡片，並主攻塑膠鏡片領域。2002 年手機開始導入照相功能後由於塑膠鏡片具成本優勢，公司藉由優異的模具設計及開發能力成為全球手機高階鏡頭領導廠商。1Q24 產品組合：20M 以上 20-30%、10M 以上 40-50%、8M 0-10%、others 20-30%。

主要客戶：APPLE、華為

主要競爭對手：Kantatsu、舜宇光、玉晶光

廖貫捷 kuanchieh.liao@sinopac.com

大立光 (3008 TT)

營運轉折可期


永豐觀點

大立光 1Q24 營利率符合預期，受惠價報價壓力見底、潛望式鏡頭良率持續改善以及採用機種擴大，營利率轉折點落於 2Q24 並延續至 4Q24 趨勢不變。

投資評價與建議


大立光 1Q24 財報符合預期，2Q24 在報價壓力見底及良率持續改善下營利率 YoY 迎來轉折，2H24 在潛望式鏡頭機種向下滲透以及大尺寸 CIS 帶動鏡片放大，HoH+81.9%旺季效應可期，投資建議維持買進，目標價 3020 元(20 X 2024 EPS)。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Apr. 2024

近八季營業利益及毛利率趨勢圖




資料來源：CMoney；永豐投顧研究處整理，Apr. 2024

營運現況與分析

大立光為專業機鏡頭製造商：大立光成立於 1987 年，主要生產光學鏡頭及鏡片，並主攻塑膠鏡片領域，2002 年手機開始導入照相功能後由於塑膠鏡片具成本優勢，公司藉由優異的模具設計及開發能力成為全球手機高階鏡頭領導廠商。1Q24 產品組合：20M 以上 20-30%、10M 以上 40-50%、8M 0-10%、others 20-30%，主要客戶為 APPLE 以及華為，競爭對手包含 Kantatsu、舜宇光以及玉晶光。

圖一：大立光 1Q24 產品組合



資料來源：大立光、永豐投顧研究處預估及整理，Apr. 2024

1Q24 營利率符合預期：大立光 1Q24 稅後 EPS 45.77 元大幅優於研究處預估的 24.83 元水準，主要原因來自新台幣貶值 4.1% 貢獻匯兌利益 23.4 億元，EPS 影響數約 16.03 元。觀察本業表現營利率 35.0% 符合研究處預期 35.3% 水準，暗示潛望式鏡頭生產良率持續改善，整體而言大立光 1Q24 營運表現符合預期。

2Q24 進入淡季，營收 QoQ-7.6%：展望 2Q24，大立光 4-5 月接單動能與 3 月相當，6 月訂單能見度尚不明朗，研究處認為在 iPhone 淡季效應下營運 QoQ 仍呈現下滑，惟整體需求略優於年初預期，預估營收 104.58 億元(-7.6%QoQ，+27.6%YoY)，毛利率 49.3%，營利率受惠價格壓力見底以及潛望式鏡頭良率持續拉升來到 35.4%，較 2Q23 增加 1.8 個百分點迎來轉折，預估稅後淨利 28.34 億元(-53.6%QoQ，-23.3%YoY)，稅後 EPS 21.23 元(原估 20.15 元)。

表一：大立光 1Q24 財報及 2024 年獲利預估調整

百萬元	1Q24(實際)	1Q24(原估)	差異(%)	2024(新估)	2024(原估)	差異(%)
營業收入	11,313	11,260	0.47	61,374	60,791	0.96
營業毛利	5,563	5,321	4.54	32,689	31,209	4.74
營業費用	1,602	1,350	18.67	7,282	6,600	10.33
營業利益	3,961	3,971	-0.26	25,407	24,609	3.24
稅前淨利	7,430	4,065	82.77	29,158	24,985	16.70
稅後淨利	6,111	3,315	84.33	23,644	20,160	17.28
每股盈餘(元)	45.77	24.83		177.11	151.01	
Margin(%)						
營業毛利率	49.17	47.26	--	53.26	51.34	--
營業利益率	35.01	35.27	--	41.40	40.48	--
稅前淨利率	65.68	36.10	--	47.51	41.10	--
稅後淨利率	54.02	29.44	--	38.53	33.16	--

資料來源：永豐投顧研究處預估及整理，Apr. 2024

潛望式鏡頭機種向下滲透，2H24 旺季效應可期：展望 2024 年，研究處認為 ASP 較傳統鏡頭倍數提升的 iPhone 潛望式鏡頭採用機種可望於 2H24 向下滲透，預估營收貢獻由 4Q23 的 13.5% 提升至 4Q24 的 21.3%。另一方面隨著手機品牌廠採用大尺寸 CIS，對應鏡頭鏡片亦同步放大將持續推升 ASP，帶動 2H24 營收 HoH+81.9%，研究處微幅上調 2024 年營收至 613.74 億元(+25.7%YoY)，毛利率 53.3%，稅後淨利 236.44 億元(+32.0%YoY)，稅後 EPS 177.11 元(原估 151.01 元)。

維持 2Q24 迎來營利率轉折不變：觀察大立光股價走勢與營利率相符，自 3Q17 以來股價反映 iPhone X 銷售不如預期，導致營利率下滑，近年受制於華為退出市場、鏡頭規格升級趨勢放緩、iPhone 扶持競爭對手以及手機庫存調整影響，大立光在稼動率及產品組合腹背受敵下營利率逐季走低，連帶使得股價持續修正。展望 2024 年，研究處預期美系客戶潛望式鏡頭使用機種數攀升以及良率改善下，1Q24 營利率 35.0% 為全年低點，營利率轉折點落於 2Q24 不變並延續正成長趨勢至 4Q24，可望為後續股價得到支撐。

附表一：當年度損益表

單位：百萬元	24Q1F	24Q2F	24Q3F	24Q4F	2024F
營業收入	11,313	10,458	17,499	22,103	61,374
營業毛利	5,563	5,155	9,383	12,588	32,689
營業利益	3,961	3,705	7,133	10,608	25,407
稅前淨利	7,430	3,799	7,227	10,702	29,158
稅後純益	6,111	2,834	5,947	8,752	23,644
稅後 EPS (元)	45.77	21.23	44.55	65.56	177.11
營收 QoQ 成長率	-36.74	-7.56	67.33	26.31	--
營收 YoY 成長率	23.83	27.63	28.40	23.60	25.66
毛利率	49.17	49.29	53.62	56.95	53.26
營益率	35.01	35.43	40.76	47.99	41.40
稅後純益率	54.02	27.10	33.98	39.60	38.52

資料來源：CMoney；永豐投顧研究處整理，Apr. 2024

附表二：五個年度損益表

單位：百萬元	2020	2021	2022	2023	2024F
營業收入	55,944	46,962	47,675	48,842	61,374
% 變動率	-7.90	-16.06	1.52	2.45	25.66
營業毛利	37,468	28,149	26,096	23,806	32,689
毛利率 (%)	66.97	59.94	54.74	48.74	53.26
營業淨利	32,032	23,148	20,384	17,807	25,407
稅前淨利	31,694	23,027	27,827	22,102	29,158
% 變動率	-13.35	-27.35	20.85	-20.57	31.92
稅後純益	24,534	18,671	22,625	17,902	23,644
% 變動率	-13.19	-23.90	21.18	-20.87	32.07
稅後 EPS * (元)	182.90	139.28	169.52	134.13	177.11
市調 EPS * (元)	192.75	141.04	175.93	136.13	164.13
PER (x)	12.66	16.62	13.66	17.26	13.07
PBR (x)	2.20	2.19	1.99	1.87	1.72
每股淨值 * (元)	1,049.98	1,056.97	1,161.87	1,239.78	1,348.89
每股股利 (元)	91.50	70.16	85.50	67.50	--
殖利率 (%)	3.27	3.15	4.40	2.39	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理，Apr. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

倫敦	永豐金證券(歐洲)有限公司 6 Lloyds Avenue, London EC3N 3AX, UK 電話：(44-20) 7614-9999
----	---

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Notice for UK Persons**

This Document may only be issued or passed on to any person in the United Kingdom if that person is of a kind described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2001 or otherwise pursuant to exemptions to section 21 of the Financial Services and Markets Act 2000. In addition, no person who is an Authorized Person may issue or pass on this document, or otherwise promote SPSE, to any person in the United Kingdom other than by the rules of the Financial Conduct Authority (FCA) applicable to such Authorized Persons. This Document is confidential and is intended solely for the use of its recipient.

Important Disclosures for U.S. Persons

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.

SinoPac Securities (Europe) Limited is regulated by the FCA